MTOR and hepatocellular carcinoma: In addition, Alpelisib presented synergistic efficacy in PIK3CA mutant HCC in combination with mechanistic target of rapamycin kinase (mTOR) or cyclin-dependent kinase (CDK) 4/6 inhibitors [26].